Gabriel N. Hortobágyi
0000-0002-4873-4412
Publication & Citation Trends
Most Cited Works
Publications
1,904 total
Long-Term follow-up of S0221, comparing alternative Dose-Schedules of anthracycline/taxane therapy in early breast cancer.
Cited by 0
Semantic Scholar
LBA14 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 5-year outcomes
Cited by 4
Semantic Scholar
Adjuvant ribociclib plus nonsteroidal aromatase inhibitor therapy in patients with HR-positive/HER2-negative early breast cancer: 5-year follow-up of NATALEE efficacy outcomes and updated overall survival
Cited by 14
Semantic Scholar
Ribociclib Plus Endocrine Therapy in Hormone Receptor–Positive/ERBB2-Negative Early Breast Cancer
Cited by 14
Semantic Scholar
FGFR3-induced Y158 PARP1 phosphorylation promotes PARP inhibitor resistance via BRG1/MRE11-mediated DNA repair in breast cancer models
Cited by 5
Semantic Scholar
Reply to Letters to the Editor by Mimura et al. and Hu and Yang regarding the NATALEE final invasive disease-free survival analysis.
Cited by 0
Semantic Scholar
Cognitive Impairment and Chemoendocrine vs Endocrine Therapy in Pre- and Postmenopausal Women: A Secondary Analysis of the RxPONDER Randomized Clinical Trial.
Cited by 2
Semantic Scholar
Novel Postneoadjuvant Prognostic Breast Cancer Staging System.
Cited by 4
Semantic Scholar
Research Topics
Breast Cancer Treatment Studies
(609)
Cancer Treatment and Pharmacology
(467)
HER2/EGFR in Cancer Research
(432)
Advanced Breast Cancer Therapies
(262)
Cancer Genomics and Diagnostics
(193)
Frequent Co-Authors
Affiliations
Université Paris-Sud
Boston University
Northwestern University
Hiroshima University
Goethe University Frankfurt